Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

McKemey joins Certara to accelerate growth of its strategic drug development solutions

RADNOR, PA – March 5th, 2025 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara’s global team of drug development scientists.

Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with the Boston Consulting Group (BCG) working in the Life Sciences practice in New York. He holds a BSc (First Class) and a PhD in High Energy Nuclear Particle Physics from the University of London.

The change is part of a planned leadership transition. Patrick Smith, PharmD. will continue to support Certara’s growth in science and innovation as Senior Vice President of Translational Sciences. Patrick and his leadership team successfully led and integrated the Certara services team building a unified offering of comprehensive scientific services for life sciences clients across the globe.

“Adrian brings a mission-driven approach to improving drug development,” said William Feehery, Ph.D., Certara’s CEO. “His leadership will build upon recent accomplishments helping Certara further scale its biosimulation and scientific services to support the next generation of life-changing therapies.”

“Certara’s leadership in biosimulation is key to de-risking the thorny issues I have seen the industry tackle for decades in clinical development. The rising adoption of in silico models into portfolio decision making can improve the probability of success at the asset and aggregate portfolio level,” said Adrian McKemey. “This role and the Certara portfolio present an ideal opportunity for me to positively impact the industry and accelerate medicines to patients.”